

Melan-A (26-35)/Melan-A (31-96)/tyrosinase (1-9)/tyrosinase (369-377) Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0449

DESCRIPTION	
Product Name	Melan-A (26-35)/Melan-A (31-96)/tyrosinase (1-9)/tyrosinase (369-377) Circular RNA for Cancer Vaccine Research
Gene Name	Melan-A (26-35)/Melan-A (31-96)/tyrosinase (1-9)/t
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Synchrovax SEM Plasmid DNA Vaccine
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	Melan-A (26-35)/Melan-A (31-96)/tyrosinase (1-9)/tyrosinase (369-377)
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Synchrovax SEM Plasmid DNA Vaccine

(1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth. (NCIT_C28549).

Background

Description: A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase